15.81
Schlusskurs vom Vortag:
$15.56
Offen:
$15.56
24-Stunden-Volumen:
738.01K
Relative Volume:
0.69
Marktkapitalisierung:
$789.77M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-156.39M
KGV:
-4.2846
EPS:
-3.69
Netto-Cashflow:
$-123.06M
1W Leistung:
+4.22%
1M Leistung:
+30.12%
6M Leistung:
+84.70%
1J Leistung:
+4.43%
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Firmenname
Kalvista Pharmaceuticals Inc
Sektor
Branche
Telefon
(857) 999-0075
Adresse
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Vergleichen Sie KALV mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
KALV
Kalvista Pharmaceuticals Inc
|
15.81 | 757.80M | 0 | -156.39M | -123.06M | -3.69 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-01-31 | Eingeleitet | JMP Securities | Mkt Outperform |
2025-01-07 | Eingeleitet | TD Cowen | Buy |
2024-12-18 | Eingeleitet | BofA Securities | Buy |
2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
2019-07-29 | Eingeleitet | SVB Leerink | Outperform |
2019-03-20 | Eingeleitet | Needham | Buy |
2018-10-30 | Eingeleitet | Jefferies | Buy |
2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
2017-08-31 | Eingeleitet | BTIG Research | Buy |
Alle ansehen
Kalvista Pharmaceuticals Inc Aktie (KALV) Neueste Nachrichten
What drives KalVista Pharmaceuticals Inc. stock priceOutstanding yields - jammulinksnews.com
What analysts say about KalVista Pharmaceuticals Inc. stockSuperior trading gains - jammulinksnews.com
Is KalVista Pharmaceuticals Inc. a good long term investmentRapid return acceleration - jammulinksnews.com
Friedreich's Ataxia Market Is Expanding Due To Advancing - openPR.com
KalVista Pharmaceuticals Inc. Stock Analysis and ForecastFree Consultation - Autocar Professional
Kalvista Pharmaceuticals stock maintains Market Outperform rating at JMP By Investing.com - Investing.com South Africa
Kalvista Pharmaceuticals stock maintains Market Outperform rating at JMP - Investing.com India
Kalvista's Ekterly OK'd as on-demand HAE swelling attack treatment in UK - Angioedema News
(KALV) Proactive Strategies - news.stocktradersdaily.com
JMP reiterates Market Outperform rating on Kalvista stock after UK approval By Investing.com - Investing.com South Africa
JMP reiterates Market Outperform rating on Kalvista stock after UK approval - Investing.com Nigeria
KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - BioSpace
KalVista Pharmaceuticals Gets UK Approval for Hereditary Angioedema Treatment - MarketScreener
KalVista Pharmaceuticals announces UK MHRA approval of Ekterly (sebetralstat) - MarketScreener
KalVista gets UK nod for Ekterly (KALV:NASDAQ) - Seeking Alpha
UK approves first oral treatment for hereditary angioedema attacks By Investing.com - Investing.com Canada
(sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - Business Wire
MHRA approves Ekterly to treat HAE - The Pharma Letter
KalVista Pharmaceuticals Wins UK Approval for Hereditary Angioedema Treatment - MarketScreener
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Have Insiders Sold KalVista Pharmaceuticals Shares Recently? - simplywall.st
The week in pharma: action, reaction and insight – week to July 11 - The Pharma Letter
Kalvista stock maintains Buy rating at H.C. Wainwright on favorable Ekterly label - Investing.com Nigeria
KalVista:HC Wainwright Raises PT to $27, Maintains Buy Rating - AInvest
Kalvista Pharma chief development officer sells $474k in shares By Investing.com - Investing.com Canada
KalVista Pharmaceuticals: EKTERLY Launch and Financial Update - TipRanks
Kalvista Pharma chief development officer sells $474k in shares - Investing.com Australia
Kalvista Pharma CEO Palleiko sells $517k in shares By Investing.com - Investing.com South Africa
Kalvista Pharma CEO Palleiko sells $517k in shares - Investing.com Australia
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results - BioSpace
KalVista price target raised to $27 from $19 at Citizens JMP - MSN
KalVista Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Leerink Partners reiterates Outperform rating on Kalvista stock as Ekterly launch begins By Investing.com - Investing.com South Africa
Leerink Partners reiterates Outperform rating on Kalvista stock as Ekterly launch begins - Investing.com Nigeria
KalVista Shares Fall After Fiscal 2025 Results - MarketScreener
KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally? - TradingView
KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended April 30, 2025 - MarketScreener
Kalvista Pharmaceuticals Inc reports results for the quarter ended April 30Earnings Summary - TradingView
Kalvista Pharmaceuticals IncFDA approves Kalvista's Ekterly for hereditary angioedema - MarketScreener
KalVista price target raised to $37 from $22 at BofA - Yahoo Finance
Finanzdaten der Kalvista Pharmaceuticals Inc-Aktie (KALV)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):